<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02715115</url>
  </required_header>
  <id_info>
    <org_study_id>Neu-2566-RETT-002</org_study_id>
    <nct_id>NCT02715115</nct_id>
  </id_info>
  <brief_title>A Safety Study of NNZ-2566 in Pediatric Rett Syndrome</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of the Safety and Pharmacokinetics of Oral NNZ-2566 in Pediatric Rett Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuren Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>rettsyndrome.org</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Neuren Pharmaceuticals Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the&#xD;
      treatment of Rett syndrome in children and adolescents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rett syndrome is a neurodevelopmental disorder primarily affecting females. The disorder is&#xD;
      characterized by apparent normal development in early infancy (6-18 months), followed by a&#xD;
      period of regression with onset of systemic and neurological signs. The CNS symptoms of Rett&#xD;
      syndrome include learning disability, autism symptomatology and epilepsy and these can be&#xD;
      severe and highly debilitating. Affected individuals also show signs of autonomic&#xD;
      dysfunction, reflected in cardiovascular and respiratory abnormalities. There is no currently&#xD;
      effective treatment for Rett syndrome.&#xD;
&#xD;
      This study will investigate the safety, tolerability and blood pharmacokinetics of treatment&#xD;
      with oral administration of NNZ-2566 at 50 mg/kg, 100 mg/kg, 200 mg/kg BID, or placebo BID,&#xD;
      in children and adolescent females with Rett syndrome. The study also will also investigate&#xD;
      measures of efficacy and biomarkers during treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">January 5, 2017</completion_date>
  <primary_completion_date type="Actual">January 5, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Through study completion, an average of 11 weeks</time_frame>
    <description>Incidence of adverse events (AEs), including serious adverse events (SAEs), will be compared across the three NNZ-2566 doses and placebo. SAEs and AEs will be examined throughout the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Motor Behaviour Assessment Scale (MBA)</measure>
    <time_frame>Through study completion, an average of 11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Improvement (CGI-I)</measure>
    <time_frame>Through study completion, an average of 11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver Top 3 Concerns via a Visual Analogue Scale (VAS)</measure>
    <time_frame>Through study completion, an average of 11 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Rett Syndrome</condition>
  <arm_group>
    <arm_group_label>NNZ-2566</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycyl-L-2-Methylpropyl-L-Glutamic Acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (strawberry flavored solution)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Strawberry flavored solution and Water for Injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNZ-2566</intervention_name>
    <description>Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.</description>
    <arm_group_label>NNZ-2566</arm_group_label>
    <other_name>trofinetide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Strawberry flavored solution and Water for Injection</description>
    <arm_group_label>Placebo (strawberry flavored solution)</arm_group_label>
    <other_name>Strawberry flavoring</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of classic/typical Rett syndrome with a documented mutation of the MeCP2&#xD;
             gene.&#xD;
&#xD;
          -  Age 5 - 15 years.&#xD;
&#xD;
          -  Weight at Screening and Baseline between 15.0 kg-100.0 kg (at least 15.0 kg and no&#xD;
             greater than 100.0 kg).&#xD;
&#xD;
          -  Each subject must be able to swallow the study medication provided as a liquid&#xD;
             solution, or via gastrostomy tube.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Actively undergoing neurological regression&#xD;
&#xD;
          -  Abnormal QT interval, prolongation or significant cardiovascular history.&#xD;
&#xD;
          -  Current treatment with insulin.&#xD;
&#xD;
          -  Anti-convulsants with liver enzyme inducing effects.&#xD;
&#xD;
          -  Unstable seizure profile.&#xD;
&#xD;
          -  Excluded concomitant medications.&#xD;
&#xD;
          -  Current clinically significant (as determined by the investigator). cardiovascular,&#xD;
             renal, hepatic, or respiratory disease.&#xD;
&#xD;
          -  Gastrointestinal disease which may interfere with the absorption, distribution,&#xD;
             metabolism or excretion of the study medication.&#xD;
&#xD;
          -  History of, or current cerebrovascular disease or brain trauma.&#xD;
&#xD;
          -  History of, or current clinically significant endocrine disorder, e.g. hypo- or&#xD;
             hyperthyroidism, or diabetes mellitus.&#xD;
&#xD;
          -  History of, or current, malignancy.&#xD;
&#xD;
          -  Significant hearing and/or visual impairments that may affect ability to complete the&#xD;
             test procedures.&#xD;
&#xD;
          -  Allergy to strawberry.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Glaze, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Percy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy Feyma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gillette Children's Specialty Healthcare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Heydemann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeff Neul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tim Benke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Colorado</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary Jones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF Benioff Children's Hospital Oakland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steve Skinner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Greenwood Genetic Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mustafa Sahin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sarika Peters, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shannon Standridge</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Marsh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hosptial Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gillette Children's Specialty Healthcare</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenwood Genetic Center</name>
      <address>
        <city>Greenwood</city>
        <state>South Carolina</state>
        <zip>29646</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 21, 2016</study_first_submitted>
  <study_first_submitted_qc>March 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2016</study_first_posted>
  <disposition_first_submitted>January 22, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>January 28, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 31, 2018</disposition_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autism</keyword>
  <keyword>Rett's syndrome</keyword>
  <keyword>Rett disorder</keyword>
  <keyword>Rett's disorder</keyword>
  <keyword>Ataxia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rett Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

